Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > BUSINESS
BUSINESS
- Takeda Launches Zacras Combination Tablets
June 20, 2014
- DSP Now Renamed “Sumitomo Dainippon Pharma” in English
June 19, 2014
- Serious ADRs Reported in Xeljanz EPPV Include Heart Failure, Pneumonia: Prof.
June 19, 2014
- Novartis Begins Global Filings for PV Treatment Ruxolitinib following Positive PIII Results
June 19, 2014
- Ono Calls Off License Pact with German Peer Merck for ONO-4641
June 19, 2014
- Japan Vaccine President and Chairman Swap Posts
June 19, 2014
- Fycompa Meets Primary Endpoints in Patients with PGTC Seizures in PIII Study: Eisai
June 19, 2014
- Takeda UC, CD Treatment Entyvio Goes on Sale in US
June 18, 2014
- Selexipag Meets Primary Endpoint in PIII GRIPHON Study: Nippon Shinyaku
June 18, 2014
- Canagliflozin Shows Significant Improvement in Glycemic Control against Placebo in PIII Study: MTPC
June 18, 2014
- Sawai Seeks US Approval for Livalo Generic, Submits ANDA
June 17, 2014
- Takeda to Withdraw US NDA for Anemia Drug, Cancel Deal with Affymax
June 17, 2014
- Meiji Seika Pharma, Fresenius Kabi Japan Terminate Alliance for Generic Drugs
June 17, 2014
- AZ to Shuffle Sales, Marketing Units, Focus on 3 Disease Areas
June 16, 2014
- Meiji Seika Pharma to Acquire Indian Generic Drug Maker Medreich for US$290 Million
June 16, 2014
- Ex-Novartis Employee Suspected of Manipulating the Number of Events in Sub-Analysis
June 13, 2014
- Teijin Now Largest Shareholder of Kyorin Holdings, Owns 19.12% Stake
June 13, 2014
- Takeda Debuts Aspirin-PPI Combination Drug Takelda in Japan
June 13, 2014
- Valeant Wins US Approval for Kaken’s Onychomycosis Drug
June 12, 2014
- Daiichi Sankyo Initiates Development of Novel, Versatile Vaccine Adjuvant
June 12, 2014
ページ
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…